Jaguar Health (JAGX) Common Equity (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Common Equity of -$15.8 million for Q1 2026, down 1997.83% year-over-year from $830000.0 in Q1 2025, and up 15.71% quarter-over-quarter from -$18.7 million in Q4 2025.
Jaguar Health (JAGX) Common Equity (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Common Equity for 13 consecutive years, with -$15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 1997.83% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$15.8 million (down 1997.83% YoY), while the FY2025 annual figure was -$18.7 million, down 387.77% from the prior year.
- Common Equity improved to -$15.8 million in Q1 2026 per JAGX's latest filing, from -$18.7 million in the prior quarter.
- Across five years, Common Equity topped out at $16.6 million in Q2 2024 and bottomed at -$18.7 million in Q4 2025.
- Historically, Common Equity has averaged $3.4 million across 5 years, with a median of $4.9 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity soared 824.93% — and 2026, when it sank 1997.83%.
- Jaguar Health's Common Equity stood at -$1.4 million in 2022, then surged by 460.34% to $4.9 million in 2023, then jumped by 32.61% to $6.5 million in 2024, then tumbled by 387.77% to -$18.7 million in 2025, then gained by 15.71% to -$15.8 million in 2026.
- Business Quant data shows JAGX's Common Equity at -$15.8 million in Q1 2026, -$18.7 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 9.79 Bn |
| 10 | Jaguar Health | 459,051.31 | -9.60 Mn | 19.11 Mn | -15.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.75 Mn |
| Dec 31, 2025 | -18.69 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 6.88 Mn |
| Mar 31, 2025 | 830,000.00 |
| Dec 31, 2024 | 6.49 Mn |
| Sep 30, 2024 | 13.10 Mn |
| Jun 30, 2024 | 16.58 Mn |
| Mar 31, 2024 | 11.82 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 5.83 Mn |
| Mar 31, 2023 | 7.66 Mn |
| Dec 31, 2022 | -1.36 Mn |
| Sep 30, 2022 | 3.60 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 8.11 Mn |
| Dec 31, 2021 | 11.85 Mn |
| Sep 30, 2021 | 21.55 Mn |
| Jun 30, 2021 | 31.79 Mn |